Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.
Vaccines are considered by many to be one of the most successful medical interventions against infectious diseases. But many significant obstacles remain, such as optimizing DNA vaccines for use in humans or large animals. The amount of doses, route and easiness of administration are also important points to consider in the design of new DNA vaccines. Heterologous prime-boost regimens probably represent the best hope for an improved DNA vaccine strategy. In this study, we have shown that heterologous prime-boost vaccination against tuberculosis (TB) using intranasal BCG priming/DNA-HSP65 boosting (BCGin/DNA) provided significantly greater protection than that afforded by a single subcutaneous or intranasal dose of BCG. In addition, BCGin/DNA immunization was also more efficient in controlling bacterial loads than were the other prime-boost schedules evaluated or three doses of DNA-HSP65 as a naked DNA. The single dose of DNA-HSP65 booster enhanced the immunogenicity of a single subcutaneous BCG vaccination, as evidenced by the significantly higher serum levels of anti-Hsp65 IgG2a Th1-induced antibodies, as well as by the significantly greater production of IFN-gamma by antigen-specific spleen cells. The BCG prime/DNA-HSP65 booster was also associated with better preservation of lung parenchyma. The improvement of the protective effect of BCG vaccine mediated by a DNA-HSP65 booster suggests that our strategy may hold promise as a safe and effective vaccine against TB.
Gonçalves
Eduardo D C
ED
Farmacore Biotecnologia Ltda, Rua dos Técnicos s/n, Campus da USP, Ribeirão Preto, SP, Brasil. eduardo@farmacore.com.br
Bonato
Vânia Luiza D
VL
da Fonseca
Denise M
DM
Soares
Edson G
EG
Brandão
Izaíra T
IT
Soares
Ana Paula M
AP
Silva
Célio L
CL
Anal Biochem. 1976 May 7;72:248-54
942051
J Immunol. 1997 Jan 1;158(1):315-21
8977205
Infect Immun. 1999 Jun;67(6):3087-95
10338525
Braz J Med Biol Res. 1999 Feb;32(2):231-4
10347759
Nature. 1999 Jul 15;400(6741):269-71
10421369
Immunology. 1999 Aug;97(4):573-81
10457209
Infect Immun. 2000 Jun;68(6):3269-74
10816472
Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):21-42
11516777
Nat Rev Immunol. 2001 Oct;1(1):20-30
11905811
J Immunol. 2002 May 1;168(9):4620-7
11971010
Immunology. 2003 Jun;109(2):295-9
12757625
J Immunol. 2003 Aug 1;171(3):1602-9
12874255
J Infect Dis. 2004 Aug 1;190(3):588-97
15243936
Immunology. 2004 Sep;113(1):130-8
15312144
Infect Immun. 2004 Nov;72(11):6471-9
15501778
J Drug Target. 2004 May;12(4):195-203
15506168
Infect Immun. 2004 Dec;72(12):6945-50
15557616
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38
15687025
Nat Med. 2005 Apr;11(4 Suppl):S33-44
15812488
Microbes Infect. 2005 May;7(5-6):962-7
15890555
J Exp Med. 2005 Jul 4;202(1):123-33
15983064
Infect Immun. 2005 Aug;73(8):5189-93
16041037
Nat Rev Immunol. 2005 Aug;5(8):661-7
16056257
Infect Immun. 2005 Nov;73(11):7759-64
16239580
Int J Infect Dis. 2006 Mar;10(2):93-102
16377228
Infect Immun. 1998 Jan;66(1):169-75
9423854